Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Memphasys has ticked off a key commercial milestone in Vietnam, securing registration for its Felix System and triggering a 600-cartridge order from local distributor TMSC Vietnam.

For investors, the importance of the development is less about the headline regulatory approval and more about what comes next. Registration converts Vietnam from a market-entry exercise into an active commercial territory, with contracted cartridge purchases, clinic engagement and early clinical use now under way.

The company said registration was achieved in August 2026, matching the timetable previously communicated to the market. The clearance allows full commercial sales of Felix to begin and activates the first major purchase under Memphasys' two-year exclusive commercialisation agreement with TMSC Vietnam.

A 600-cartridge order puts some meat on the commercial bones

The initial commercial order covers 600 Felix cartridges and sits within a two-year agreement worth A$530,000.

That contract is structured across A$205,000 in the first year and A$325,000 in the second, with quarterly cartridge volumes expected to increase as clinic adoption develops.

Importantly, the new order is not starting from zero. Memphasys had already supplied 100 cartridges and three consoles for testing, product introduction and clinical preparation. Adding the latest order takes the total number of cartridges delivered or ordered for Vietnam to 700.

That progression matters. Medical-device companies can spend years talking about market access while investors wait for regulatory approvals, distributor appointments and actual purchase orders to line up. In Vietnam, those pieces are beginning to connect.

The 600-cartridge order also forms part of previously contracted purchase commitments, so investors should distinguish between fresh incremental contract value and the execution of an existing agreement. Still, moving from contract signing to product ordering and commercial supply reduces one layer of execution risk.

The distributor has spent the past several weeks introducing Felix to clinics, meaning the commercial rollout is moving beyond regulatory paperwork and into the harder task of generating repeat usage.

Vietnam could become a useful test of the recurring revenue model

Memphasys is positioning Felix as an alternative sperm-selection system for assisted reproduction, using electrophoresis and size-exclusion membranes rather than traditional centrifugation.

The company says the system is designed to provide a fast, gentle and standardised sperm-selection process while reducing laboratory time and avoiding some of the cellular stress associated with centrifugation.

For shareholders, the commercial model is particularly relevant. Felix combines reusable consoles with consumable cartridges, meaning meaningful adoption could generate recurring cartridge revenue rather than relying solely on one-off equipment sales.

Vietnam provides an early opportunity to test whether that recurring model can translate from agreements on paper into steady clinic usage.

TMSC Vietnam appears strategically suited to the job. The Hanoi-based distributor focuses on reproductive health, diagnostics, digital health tools and medical devices, and already has relationships across the local healthcare system. Memphasys will support product education, clinical positioning and selected clinic engagement while TMSC Vietnam handles local market development and distribution.

The next question is adoption, not approval

With registration complete, the investment story in Vietnam now changes.

Regulatory timing has been delivered. The first substantial commercial cartridge order has been triggered. Clinics are being approached and at least one early pregnancy has been reported following use of Felix.

The next milestones will be more commercially demanding: how quickly clinics adopt the system, whether cartridge consumption becomes recurring, and whether volumes build in line with the contracted schedule.

Vietnam is described by Memphasys as a growing assisted reproductive technology market, supported by increased healthcare investment, rising fertility-service demand and expanding fertility infrastructure in Hanoi and Ho Chi Minh City.

That gives Felix an addressable market, but the size of the opportunity for Memphasys will ultimately depend on execution rather than demographics alone.

For investors, the Vietnam rollout is therefore entering a more informative phase. The regulatory gate has opened. What matters now is how much product moves through it.

DXN has added another high-profile infrastructure customer to its books, securing an approximately $4.1 million contract from the operator of Melbourne Airport to supply a prefabricated Edge data centre facility.

The contract covers the full project lifecycle, including design, engineering, manufacturing, factory acceptance testing, delivery, installation and commissioning. The completed facility will include critical power, cooling, fire detection and suppression systems, along with supporting infrastructure.

Manufacturing will take place within DXN's existing production network, with delivery to Melbourne Airport and commissioning targeted towards the end of the first half of calendar 2027.

For investors, the significance extends beyond the headline contract value. Melbourne Airport gives DXN an entry point into aviation and transport infrastructure, adding another end market to a customer base already spanning government, telecommunications and large enterprise users across the Asia Pacific.

Airports are particularly suitable for Edge infrastructure because many operational systems need to process data close to where it is generated. Security, communications, automation, sensing and real-time analytics can all depend on low-latency, resilient computing capacity.

That makes an operating airport a useful showcase for DXN's prefabricated model.

Prefabrication tackles the construction headache

DXN's pitch is relatively straightforward: build and test as much as possible in a controlled factory environment, then deliver the completed facility to site.

That approach can be especially valuable at locations where conventional construction is difficult, expensive or disruptive.

Melbourne Airport certainly fits the description. It is a security-controlled facility operating around the clock, meaning extended on-site construction brings obvious logistical complications.

Managing director Shalini Lagrutta said the airport was "precisely the kind of Edge site where our model delivers the most value", arguing that prefabrication shifts much of the construction risk away from the customer site while shortening delivery schedules.

Management says customers are increasingly choosing factory-built facilities rather than embarking on lengthy upgrades of existing data centres or traditional on-site builds. DXN argues that assembling and testing facilities before delivery can compress programs that might otherwise take years into months.

That trend is important to the investment case because DXN needs more than individual project wins. The larger opportunity rests on prefabricated infrastructure becoming a more widely accepted method of adding digital capacity.

The Melbourne Airport contract offers further evidence that the model can attract major infrastructure owners with mission-critical requirements.

Globalstar variation adds another $1.6 million

The airport deal was accompanied by another revenue contribution, with DXN receiving an approximately $1.6 million variation order under its existing contract with telecommunications customer Globalstar.

The additional amount relates to project fees and logistics costs.

Combined, the two items represent roughly $5.7 million of additional contract value, although investors should distinguish between a new customer contract and a variation to an existing project.

Even so, the Globalstar variation reinforces DXN's exposure to telecommunications infrastructure, an area where modular facilities can be particularly useful in remote or specialised locations.

What investors should watch next

The Melbourne Airport project strengthens DXN's credentials, but execution remains the next test.

Manufacturing, delivery, installation and commissioning are still ahead, and the project will need to progress towards its targeted commissioning timetable in the first half of 2027.

Investors will also be watching whether the airport win leads to further opportunities in aviation, transport or other infrastructure-heavy industries. One successful contract can establish credibility, but repeat business and additional customer wins would provide stronger evidence that the addressable market is expanding.

DXN operates across modular data centres, owned data centre operations in Darwin and Hobart, and a capital-light Data Centre as a Service model. The Melbourne Airport contract sits squarely within the modular division and highlights the company's effort to turn prefabricated Edge infrastructure into a broader growth platform.

For now, the key development is that DXN has landed a substantial contract with one of Australia's largest transport infrastructure operators while also increasing the value of an existing telecommunications project.

That does not remove the usual risks associated with project delivery, timing and customer concentration, but it does give investors another tangible sign that DXN's factory-built data centre model is finding customers in increasingly demanding environments.

Entropy Neurodynamics has taken another step towards turning its intravenous psilocin program into a product capable of supporting larger international trials, appointing BioCina to manufacture its proprietary TRP-8803 formulation under Good Manufacturing Practice standards.

For investors, the significance is less about producing a few more clinical vials and more about building the pharmaceutical infrastructure needed if TRP-8803 progresses into late-stage development.

BioCina will manufacture clinical drug supply while generating pharmaceutical and stability data intended to support regulatory submissions in the United States, Europe and other major markets. The work is expected to establish a manufacturing platform that can be used across Entropy's broader TRP-8803 program rather than being tied to one trial or one indication.

That distinction matters. Plenty of biotechnology programs produce promising early clinical data. Fewer reach the stage where manufacturing, quality systems, stability testing and regulatory documentation are being built with larger trials and potential commercial supply in mind.

BioCina brings regulatory and global manufacturing muscle

BioCina is a TGA-licensed contract development and manufacturing organisation with sterile manufacturing operations in Perth and Adelaide. It has experience with FDA inspections, quality systems aligned with European regulatory standards and supplies pharmaceutical products internationally.

Importantly for TRP-8803, BioCina maintains the regulatory framework needed to handle Schedule 9 active pharmaceutical ingredients, including psilocin.

The manufacturing program will include analytical verification, engineering batches and production of both GMP placebo and active drug product batches. TRP-8803 will be filled into sterile 10 mL glass vials at BioCina's Perth facility using a robotic aseptic filling line.

Entropy expects the manufacturing program to take about 24 weeks, while real-time stability studies will continue for 24 months. That longer stability program is particularly relevant because regulators need evidence that a drug product remains within specification during storage before it can be used more broadly in clinical development or, eventually, commercial settings.

BioCina chief executive Dr Thomas Broudy said the group would work with Entropy to establish "a scalable manufacturing process capable of supporting the continued development of TRP-8803".

Why IV psilocin is the strategic bet

TRP-8803 is designed to address one of the more awkward features of oral psilocybin therapy - variability.

Entropy's intravenous psilocin formulation is intended to provide more consistent therapeutic exposure while allowing clinicians greater control over the onset, intensity and duration of the psychedelic experience.

That control could become commercially important. Psychedelic-assisted therapy is not simply a drug-in, patient-out model. Treatment duration, clinical supervision and the predictability of the psychedelic experience can all influence how easily a therapy can be deployed in real-world healthcare settings.

Entropy argues that its IV approach may allow a more reproducible treatment profile and reduce the overall intervention time to a commercially workable duration.

The company has already completed Phase 2a work using oral psilocybin across binge eating disorder, irritable bowel syndrome and fibromyalgia, with those studies informing the development of TRP-8803.

A broader clinical program raises the manufacturing stakes

The timing of the BioCina deal is notable because Entropy is also expanding its clinical ambitions.

The company recently received approval for a 72-patient study assessing TRP-8803 across eight neuropsychiatric indications with high unmet clinical need. That broad development strategy increases both the potential opportunity and the operational complexity.

A multi-indication program needs a dependable source of drug product, consistent formulation standards and manufacturing data that can travel across different regulatory pathways.

Chief executive Jason Carroll said Entropy was building pharmaceutical manufacturing capability alongside its growing clinical evidence base.

"As our multi-indication development strategy advances, this agreement with BioCina ensures that as our clinical evidence base expands, TRP-8803 is supported by a manufacturing engine capable of rapid scale-up, global distribution and commercial-grade consistency," he said.

What investors should watch next

The BioCina agreement removes one development bottleneck, but it does not remove the clinical and regulatory risks that define early-stage biotechnology.

The key milestones now shift towards execution. Investors will want to see the manufacturing program completed on schedule, GMP batches successfully produced, stability data generated and the expanding clinical program deliver evidence strong enough to justify progression into larger Phase 2/3 studies.

No commercial approval is assured, and the company still needs to demonstrate that TRP-8803 delivers clinically meaningful and reproducible outcomes across its targeted indications.

One useful detail is that Entropy retains full ownership of TRP-8803 intellectual property and product-specific know-how under the manufacturing agreement. BioCina is providing the manufacturing engine rather than acquiring rights to the asset.

For Entropy, the investment proposition is therefore becoming clearer. TRP-8803 is moving beyond being simply an experimental formulation towards a program supported by clinical, manufacturing and regulatory infrastructure capable of operating internationally.

The science still has plenty to prove. But if TRP-8803 is ultimately going to become a globally deployable psychedelic therapy, scalable GMP manufacturing is not optional. Entropy has now put that piece of the puzzle in place.

Viva Leisure has used a year of network optimisation to demonstrate something investors have been waiting to see - whether the gym operator can grow earnings faster than revenue without relying on a relentless diet of new site openings.

The FY2026 numbers suggest it can.

Revenue increased 12.2 per cent to $237.1 million, while adjusted EBITDA rose 13.3 per cent to $112.3 million. Underlying pre-AASB16 EBITDA climbed 17.0 per cent to $53.7 million and underlying net profit jumped 46.4 per cent to $18.9 million. Statutory NPAT more than doubled to $12.8 million. All five financial measures tracked by management exceeded guidance, including the profit guidance upgraded in May.

The more interesting number for investors is operating costs, which rose 10.2 per cent, slower than revenue. That pushed the adjusted EBITDA margin 50 basis points higher to 47.4 per cent. Viva calculates that 51 cents of every incremental revenue dollar generated during the year became EBITDA.

That is the operating leverage the company has been promising, and FY2026 provided a useful test because expansion was deliberately restrained.

More members, almost the same number of gyms

Viva finished June with 204 corporate clubs, only three more than a year earlier, yet corporate membership increased by more than 17,000 to 275,688.

Average membership per corporate club increased from 1,286 to a record 1,351 and portfolio utilisation moved above 80 per cent. Management estimates average revenue per member at about $750 annually, implying that better utilisation across the existing estate can deliver meaningful revenue without another lease, fit-out and opening campaign.

Health clubs remain overwhelmingly the engine room, generating $208.2 million of revenue. Of the group's $25.8 million increase in annual revenue, $20.7 million came from health clubs despite the limited increase in corporate locations. Payments and technology revenue, however, grew 39.8 per cent, while supplements and other revenue rose 18.5 per cent.

Those smaller divisions matter because their growth requires considerably less physical capital.

Cash flow earns Viva its first dividend

The other change in the investment case is that expansion is increasingly being funded internally.

Adjusted free cash flow rose 7.7 per cent to $35.1 million. Viva reinvested $31.3 million across growth capex, technology and acquisitions while reducing net leverage from 2.04 times to 1.77 times. The banking covenant remains at 2.50 times.

That gave the board enough confidence to declare Viva's maiden dividend of 3.0 cents per share, fully franked. The dividend goes ex on 28 September, has a 29 September record date and is scheduled for payment on 20 October. A dividend reinvestment plan will operate without a discount.

The dividend is modest, but symbolically important. Viva is effectively arguing that it has reached the point where growth investment, deleveraging and shareholder distributions can coexist rather than compete for the same dollar.

Meridium adds another moving part

Potentially the biggest valuation wildcard is Meridium Global, the new standalone structure housing Viva's payments and technology assets.

These operations include payments processing, member-management technology, access-control hardware and Viva 360, the group's data and member-intelligence platform. Total transaction volume exceeds $400 million, while management says separating the business removes constraints around external customer access and allows it to be compared with payments and technology businesses rather than solely fitness operators.

Meridium generated $13.4 million of standalone EBITDA in FY2026 before inter-segment eliminations, up from $3.7 million in FY2025. Viva has commenced a strategic review to determine the best way to realise that value for shareholders, but no specific transaction or timetable has been outlined.

For investors, that means Meridium is optionality rather than realised value at this stage.

The growth lever gets switched back on

Having spent FY2026 proving it could extract more from the existing network, Viva now plans to accelerate openings again.

The group finished June with 694,243 network members and has subsequently passed 700,000. Its longer-term target is one million members by FY2029, supported by more than 30 new corporate and franchise locations annually and a pipeline of 170 locations already sold or contracted.

Management is pointing to a pace of more than 20 net new corporate openings from FY2027 onwards, alongside a franchise pipeline of more than 150 sites and a 20-location refurbishment program.

No specific FY2027 revenue or earnings guidance has been provided. That leaves execution as the next test: Viva has shown the economics can improve when expansion slows. Investors will now be watching whether those margins, cash conversion and leverage metrics hold up when the treadmill speeds up again.

XRF Scientific has entered FY27 with a broader product suite, new international sales offices and a capital equipment division carrying considerably more momentum than it had a year ago.

The laboratory technology group delivered FY26 revenue of $64.4 million, up 8%, while adjusted profit before tax increased 10% to $16.1 million. Statutory net profit after tax edged 1% higher to $10.5 million after the company absorbed acquisition expenses and the costs of establishing new offices in India and the US.

The result was stronger beneath the statutory headline. Gross margin improved to 49.3% from 48.4%, operating cash flow rose to $11.4 million and the June quarter produced record adjusted profit before tax of $4.7 million on revenue of $17.2 million. The company declared a fully franked dividend of 4.5 cents per share.

Capital equipment becomes the growth engine

The standout performer was Capital Equipment, where revenue increased 17% to $26.3 million and profit before tax jumped 29% to $5.3 million. The division's profit margin improved to 20% from 18%.

Orbis laboratory crushers were a major contributor, with revenue rising 26% to $8.9 million. Demand came from Australia, the US and Canada, predominantly from gold sector customers.

The appeal of the Orbis range is reasonably easy to understand. The equipment can reduce 110 millimetre drill core samples to 2 millimetres in a single pass, automate sample splitting and reduce manual handling. In mining laboratories, where speed, consistency and operator safety all matter, those characteristics give the product a clear industrial use case.

The newer xrTGA thermogravimetric analyser is also beginning to gain traction. FY26 sales reached $1 million and, importantly, XRF Scientific recorded repeat sales from two large global companies. Management expects the product line to develop into a material contributor to Capital Equipment.

That makes FY27 less dependent on one product family. The company has also released next-generation xrFuse machines and says more than six additional machines are under development for release through FY27 and beyond.

CGA acquisition adds another leg

The acquisition of the CGA Elemental Analysis Instrument business from Bruker AXS SE in April is central to the next phase of growth.

XRF Scientific paid upfront consideration of US$4 million, with the acquisition funded entirely from cash. The transaction expanded inventories by around $1 million and intangible assets by $6.2 million, while adding a $1.4 million acquisition earnout liability.

The acquired technology measures carbon, sulphur, oxygen, nitrogen and hydrogen across applications ranging from iron, steel and nickel production to aerospace alloys, rare earth magnets, welding and additive manufacturing.

Manufacturing is being transferred to Perth, with revenue expected to commence in the second quarter of FY27. The company is also looking to sell related consumables into the existing CGA customer base and use newly acquired distributors to cross-sell other products, including xrTGA.

For investors, that combination is worth watching because instrument sales can potentially create follow-on demand for consumables and service, broadening the revenue opportunity beyond the initial machine purchase.

Consumables steady while precious metals lift profits

Not every division grew in FY26.

Consumables revenue fell 6% to $18.1 million and profit before tax declined 6% to $6.8 million. Even so, the margin remained a healthy 38%, and the second half improved substantially, delivering $3.8 million of profit before tax compared with $3 million in the first half.

Management pointed to strong international sales, particularly in Asia, while incoming orders were described as strong early in FY27.

Precious Metals had a stronger year, with revenue rising 14% to $24.6 million and profit before tax increasing 27% to $4.5 million. Margins expanded to 18% from 16%.

Higher precious metals prices supported recycling margins, although rising platinum prices also made some customers more cautious about new product purchases during the middle of the year. Demand subsequently improved as platinum prices eased.

Balance sheet still leaves room to move

Despite acquisition spending and dividends, XRF Scientific finished FY26 with $9.5 million in cash and a net cash position of $8.5 million.

Operating cash flow of $11.4 million exceeded statutory net profit, while investing cash outflow rose to $8.1 million, including $5.6 million associated with the CGA acquisition. The company also paid $5 million in cash for the FY25 dividend.

Inventories increased 12% to $21 million and intangible assets rose 38% to $23.9 million, largely reflecting the acquisition, while total equity increased 10% to $66.3 million.

The balance sheet therefore remains relatively lightly geared as management continues to pursue complementary laboratory product manufacturing and supply businesses.

FY27 shifts the focus from groundwork to execution

The FY27 strategy is built around integrating CGA, expanding Orbis and xrTGA sales, ramping up the new India and US offices, releasing new machines and continuing acquisition activity.

The ingredients for growth are more numerous than they were a year ago. The key question is whether those investments translate into sustained revenue growth without diluting the margins and cash conversion that have become important features of the business.

With Capital Equipment accelerating, international distribution expanding and several new products moving towards commercialisation, FY27 is shaping up as an execution year rather than simply another year of product development.